One ticker, one page: health score, red flags, fundamentals, who’s buying, cash & dilution, and the latest catalyst — every module built from SEC filings, ready to print or share.
start from a preset — you get the bundle, then edit it
or pick exactly what you want — 5 selected
These add one extra lookup each — still fine to combine.
Heavy modules — each one runs on its own. Checking one clears the rest, because it reads several filings live and would otherwise time the page out.
Your selection lives in the link, so a built report is shareable and bookmarkable. Educational information from public filings — not investment advice.
Assembling MLTX’s research report…
Pulling SEC filings
Parsing XBRL fundamentals
Scoring quality, value & momentum
Checking who’s buying
Rendering
MLTX MOONLAKE IMMUNOTHERAPEUTICS
Research report · from SEC EDGAR · close 2026-11-02
$11.47 -2.6%
$976.2M mkt cap
Close: REPORTED End-of-day closing price; as of 2026-11-02. No single source document identified.
Market cap: DERIVED Last close times filed shares outstanding, dei:EntityCommonStockSharesOutstanding; as of close 2026-11-02; count as of 2026-08-01; Form 10-Q 0001821586-26-000010, filed 2026-08-10.
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) is a $976.2M company. It is not yet profitable. Our health score is F (13/100). 2 red flags on file. It may need to raise cash (dilution risk).
Market cap: DERIVED Last close times filed shares outstanding, dei:EntityCommonStockSharesOutstanding; as of close 2026-11-02; count as of 2026-08-01; Form 10-Q 0001821586-26-000010, filed 2026-08-10.
Net income: REPORTED SEC XBRL companyfacts, us-gaap:NetIncomeLoss; as of FY ending 2025-12-31; Form DEF 14A 0001140361-26-015916, filed 2026-04-21.
Health score: UNVALIDATED StockTools.ai health score, from SEC XBRL companyfacts and end-of-day prices; as of cash as of 2026-06-30; trend at close 2026-11-02. Method not verified against an independent source.
Insider counts: DERIVED SEC Form 4, open-market purchases (P) and sales (S); as of filed 2026-05-13 to 2026-07-29.
Congress counts: DERIVED Periodic transaction reports filed under the STOCK Act; as of no report in the window read. No single source document identified; no as-of date carried.
SEC Form 13F-HR, the funds we track; as of no tracked fund reports a position.
Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
REPORTED SEC full-text search for "substantial doubt" in 10-K and 10-Q filings; as of filed 2025-07-31 to 2026-11-03.
⚠
Active dilution shelf
An effective S-3 shelf with 3 prospectus filing(s) in 12 months — shares may be getting sold into the market.
REPORTED SEC EDGAR filing index, shelf registrations (S-3, F-3) and 424B prospectuses, S-3ASR; as of shelf filed 2026-08-10, effective 2026-08-10.
who's buying
Insider buys / sells
0 / 10
DERIVED SEC Form 4, open-market purchases (P) and sales (S); as of filed 2026-05-13 to 2026-07-29.
Congress buys
0
DERIVED Periodic transaction reports filed under the STOCK Act; as of no report in the window read. No single source document identified; no as-of date carried.
13F fund holders
0
DERIVED SEC Form 13F-HR, the funds we track; as of no tracked fund reports a position. No single source document identified; no as-of date carried.
No per-share dividend series in MLTX’s filings — either it pays none, or it doesn’t report the tag we read. We show nothing rather than estimate.
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices. Each figure prints its own source and the date it is true as of beneath it, with REPORTED for a figure the source published and DERIVED or UNVALIDATED for our arithmetic; nothing is fabricated or predicted. Filings lag 40 to 90 days. Educational, not investment advice. Generated 2026-11-03 by stocktools.ai.
No single source document identified; no as-of date carried.
Cash need: DERIVED Cash divided by operating burn, from SEC XBRL companyfacts; as of cash as of 2026-06-30; operating cash flow over FY ending 2025-12-31.